Showing 2041-2050 of 3038 results for "".
- Novartis Launches App to Collect Patient Data in Studies for Ophthalmic Diseaseshttps://modernod.com/news/novartis-launches-app-to-collect-patient-data-in-studies-for-ophthalmic-diseases/2480209/Novartis announced the launch of its FocalView app, an ophthalmic digital research platform that aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routin
- Registration Now Open for Neuro-Optometric Rehabilitation Associationhttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association/2480217/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) Clinical Skills Pre-Conference (September 20-21) and 27th annual General Conference (September 21-23) at the Hyatt Regency in St. Louis. CLINICAL SKILLS PRE-CONFERENCE (
- Novartis Confirms 2018 Targets as Alcon Recovery Gains Steamhttps://modernod.com/news/novartis-confirms-2018-targets-as-alcon-recovery-gains-steam/2480224/Swiss drugmaker Novartis’ first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit, according to a
- Alcon Adds New Gemstone Collection to Air Optix Colors Lens Portfolio and Introduces 2-Count Packshttps://modernod.com/news/alcon-adds-new-gemstone-collection-to-air-optix-colors-lens-portfolio-and-introduces-2-count-packs/2480236/Alcon has introduced its new Air Optix Colors Gemstone Collection of color contact lenses, with three new colors – Amethyst, True Sapphire, and Turquoise. Now offering a total of 12 colors, Air Optix Colors lenses appeal to a wide range of patients and offer a strong incremental revenue potential
- EyePoint Pharmaceuticals Strengthens Global IP With Notices of Allowance for Two U.S. Patents Related to Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-strengthens-global-ip-with-notices-of-allowance-for-two-u-s-patents-related-to-dexycu/2480252/EyePoint Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patents covering Dexycu, the company’s FDA-approved long-acting intraocular product for the treatment of postoperative inflammation. The first patent (U.S. patent ap
- Oculis Begins Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Diseasehttps://modernod.com/news/oculis-begins-phase-2b-relief-trial-of-topical-anti-tnfa-licaminlimab-ocs-02-in-dry-eye-disease/2481998/Oculis announced 'First Patient First Visit' (FPFV) in its phase 2b RELIEF trial evaluating the potential of licaminlimab (also known as OCS-02), Oculis’ anti-TNFα biologic eye drop drug candidate for the treatment of dry eye disease (DED). The phase 2b REL
- BostonSight Expands Scleral Lens Portfolio with New Smaller Diameter Optionshttps://modernod.com/news/bostonsight-expands-scleral-lens-portfolio-with-new-smaller-diameter-options/2486629/Key Takeaways BostonSight introduced three new smaller BostonSight Scleral lens diameters available in a single FitKit for both eyes
- Apotex Expands Canadian Ophthalmology Portfolio With Health Canada's Approval of Clobivishttps://modernod.com/news/apotex-expands-canadian-ophthalmology-portfolio-with-health-canadas-approval-of-clobivis/2486385/Key Takeaways Apotex announced that Health Canada has approved Clobivis (clobetasol propionate ophthalmic suspension 0.05%) for the treatment of postoperative inflammation and pain following cataract surgery The company stated that the product’s approval mar
- TP-03 Now Approved in China for the Treatment of Demodex Blepharitishttps://modernod.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486355/Key Takeaways TP-03 (XDEMVY) has been approved in China by the NMPA for treating Demodex blepharitis, marking a major expansion beyond th
- RevolutionEHR Announces Early Access to Redesigned Patient Portalhttps://modernod.com/news/revolutionehr-announces-early-access-to-redesigned-patient-portal/2485693/RevolutionEHR, a cloud-based electronic health record and practice management platform for optometry,